Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.39 |
| ▸ | CDC25B | P30305 | 8/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 7/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 5/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
| ▸ | CDC25A | P30304 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20755817 | 0.90 | PTPN1 (0.37) | BCHEPTPN1CDC25BPTPN2TMPRSS2 | |
| SCHEMBL19343920 | 0.86 | HTR1A (0.41) | BCHENT5ETACR2PTPN1CDC25B | |
| SCHEMBL18371663 | 0.86 | PTPN2 (0.37) | PTPN1PTPN2TMPRSS2 | |
| SCHEMBL16708470 | 0.86 | PTPN2 (0.37) | PTPN1PTPN2TMPRSS2 | |
| SCHEMBL22570013 | 0.85 | HTR1A (0.41) | BCHENT5ETACR2PTPN1CDC25B | |
| SCHEMBL17106818 | 0.81 | HTR1A (0.43) | BCHENT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL25598746 | 0.81 | HTR1A (0.43) | BCHENT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL29937393 | 0.81 | HTR1A (0.43) | BCHENT5ETACR2PTPN1CDC25B | |
| SCHEMBL29937871 | 0.81 | HTR1A (0.43) | BCHENT5ETACR2PTPN1CDC25B | |
| SCHEMBL17106820 | 0.81 | HTR1A (0.43) | BCHENT5EPTPN1CDC25BPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016280-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2018-01-18 | — | — | US | disclosed |
| US-9701682-B2 | Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2017-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016280-A1 | PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | SYNJ1, SARS1, SYNJ2 | BCHE 4586/4885NT5E 2146/4885TACR2 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.